Xenon to Present at the 45th Annual TD Cowen Healthcare Conference
Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has announced its participation in the 45th Annual TD Cowen Healthcare Conference scheduled for March 3-5, 2025, in Boston, MA.
The company will provide a live audio webcast of their presentation, which will be accessible through the 'Investors' section of Xenon's website, with a replay option available post-event.
Xenon specializes in developing ion channel products targeting epilepsy and depression. Their leading product, azetukalner, is a novel Kv7 potassium channel opener currently in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (Nasdaq: XENE), un'azienda biofarmaceutica focalizzata sulle neuroscienze, ha annunciato la sua partecipazione alla 45ª Conferenza Sanitaria Annuale TD Cowen, programmata per il 3-5 marzo 2025, a Boston, MA.
L'azienda fornirà una trasmissione audio in diretta della sua presentazione, che sarà accessibile attraverso la sezione 'Investitori' del sito web di Xenon, con un'opzione di replay disponibile dopo l'evento.
Xenon si specializza nello sviluppo di prodotti per i canali ionici mirati all'epilessia e alla depressione. Il loro prodotto di punta, azetukalner, è un nuovo apritore del canale potassico Kv7 attualmente in fase avanzata di sviluppo clinico per molteplici indicazioni.
Xenon Pharmaceuticals (Nasdaq: XENE), una empresa biofarmacéutica centrada en neurociencias, ha anunciado su participación en la 45ª Conferencia Anual de Salud TD Cowen programada para el 3-5 de marzo de 2025, en Boston, MA.
La empresa ofrecerá una transmisión de audio en vivo de su presentación, que será accesible a través de la sección 'Inversores' del sitio web de Xenon, con una opción de repetición disponible después del evento.
Xenon se especializa en el desarrollo de productos de canales iónicos dirigidos a la epilepsia y la depresión. Su producto principal, azetukalner, es un nuevo abridor del canal de potasio Kv7 que actualmente se encuentra en desarrollo clínico avanzado para múltiples indicaciones.
제논 제약 (Nasdaq: XENE)는 신경과학에 중점을 둔 생명공학 회사로, 2025년 3월 3일부터 5일까지 매사추세츠주 보스턴에서 열리는 제45회 연례 TD Cowen 헬스케어 컨퍼런스에 참여한다고 발표했습니다.
회사는 발표의 생중계 오디오 웹캐스트를 제공할 예정이며, 이는 제논 웹사이트의 '투자자' 섹션을 통해 접근 가능하고, 이벤트 후에는 재생 옵션이 제공됩니다.
제논은 간질 및 우울증을 목표로 하는 이온 채널 제품 개발에 전문화되어 있습니다. 그들의 주요 제품인 아제투칼너는 현재 여러 적응증에 대해 후기 단계의 임상 개발 중인 새로운 Kv7 칼륨 채널 개방제입니다.
Xenon Pharmaceuticals (Nasdaq: XENE), une entreprise biopharmaceutique axée sur les neurosciences, a annoncé sa participation à la 45ème Conférence Annuelle TD Cowen sur la Santé, prévue du 3 au 5 mars 2025 à Boston, MA.
L'entreprise proposera un webinaire audio en direct de sa présentation, qui sera accessible via la section 'Investisseurs' du site web de Xenon, avec une option de rediffusion disponible après l'événement.
Xenon se spécialise dans le développement de produits de canaux ioniques ciblant l'épilepsie et la dépression. Leur produit phare, azetukalner, est un nouvel ouvreur de canal potassique Kv7 actuellement en développement clinique avancé pour plusieurs indications.
Xenon Pharmaceuticals (Nasdaq: XENE), ein biopharmazeutisches Unternehmen mit Schwerpunkt auf Neurowissenschaften, hat seine Teilnahme an der 45. jährlichen TD Cowen Gesundheitskonferenz angekündigt, die vom 3. bis 5. März 2025 in Boston, MA, stattfinden wird.
Das Unternehmen wird ein Live-Audio-Webcast seiner Präsentation bereitstellen, der über den Bereich 'Investoren' auf der Website von Xenon zugänglich sein wird, mit einer Wiederholungsoption nach der Veranstaltung.
Xenon hat sich auf die Entwicklung von Ionenkanalprodukten spezialisiert, die auf Epilepsie und Depression abzielen. Ihr führendes Produkt, azetukalner, ist ein neuartiger Kv7-Kaliumkanalöffner, der sich derzeit in der späten klinischen Entwicklungsphase für mehrere Indikationen befindet.
- None.
- None.
VANCOUVER, British Columbia and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 45th Annual TD Cowen Healthcare Conference taking place in Boston, MA from March 3-5, 2025.
| Fireside Chat Presentation Details: | |
| Date: | Tuesday, March 4, 2025 |
| Time: | 10:30-11:00 AM Eastern Time |
| Webcast: | Register here |
| Presenters: | Ian Mortimer, President and Chief Executive Officer Sherry Aulin, Chief Financial Officer |
A live audio webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
FAQ
When is Xenon Pharmaceuticals (XENE) presenting at the TD Cowen Healthcare Conference 2025?
What is azetukalner and what is its development status for XENE?
Which therapeutic areas does XENE focus on in their drug development pipeline?
How can investors access Xenon's presentation at the TD Cowen Healthcare Conference?
